{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T07:32:16.711386+00:00","company":{"ticker":"AURX","cik":1091596,"company_name":"Nuo Therapeutics, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"debt_financing","fact_key":"f847e75eee5a6912c4d64db71cc20d15cc22f93d","cik":1091596,"ticker":"AURX","company_name":"Nuo Therapeutics, Inc.","filed_at":"2026-01-26T23:59:59+00:00","payload":{"counterparty":"four lenders (including Scott M. Pittman and Paul Anthony Jacobs)","effective_date":"2026-01-21","event":"incurrence","instrument_type":"credit_facility","interest_rate_text":"annual rate of 10%","item_codes_triggered":["2.03"],"maturity_text":"December 31, 2028","principal_text":"aggregate principal amount of up to $1.6 million"},"claim":"Nuo Therapeutics, Inc. incurred credit facility of aggregate principal amount of up to $1.6 million with four lenders (including Scott M. Pittman and Paul Anthony Jacobs) at annual rate of 10% maturing December 31, 2028.","evidence_excerpt":"On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million with (a) $1.0 million funded on the initial closing date (the “Initial Funding”) and (b) $600 thousand to be funded, if requested in advance by the Company and subject to closing conditions, on September 30, 2026 (the “Second Funding”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-002078","anchor_url":"https://secwatch.observer/filing/0001437749-26-002078#claim-f847e75eee5a6912c4d64db71cc20d15cc22f93d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926002078/0001437749-26-002078-index.htm"},{"fact_type":"material_agreement","fact_key":"204dd91196a3a6669ebb5f01235d860d9db485d6","cik":1091596,"ticker":"AURX","company_name":"Nuo Therapeutics, Inc.","filed_at":"2026-01-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Loan and Security Agreement","agreement_type":"credit_facility","counterparty":"four lenders (collectively, the \"Lenders\")","effective_date":"2026-01-21","item_codes_triggered":["1.01"],"value_text":"up to $1.6 million"},"claim":"Nuo Therapeutics, Inc. entered into Loan and Security Agreement with four lenders (collectively, the \"Lenders\") valued at up to $1.6 million (effective 2026-01-21).","evidence_excerpt":"On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-002078","anchor_url":"https://secwatch.observer/filing/0001437749-26-002078#claim-204dd91196a3a6669ebb5f01235d860d9db485d6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926002078/0001437749-26-002078-index.htm"}]}